Related Experiment Videos
Lipiodol retention within hepatic cavernous hemangioma
R Uflacker1, G S Mourão, R L Piske
1Med-Imagem, Hospital Beneficêncía Portuguesa, São Paulo, Brazil.
Cardiovascular and Interventional Radiology
|March 1, 1989
Summary
Intraarterial Lipiodol injection is often used to distinguish liver cancer from benign hemangiomas. However, this study found that Lipiodol retention in hemangiomas challenges its reliability for differentiating these liver lesions.
Area of Science:
- Hepatobiliary imaging
- Diagnostic radiology
- Interventional oncology
Background:
- Hepatocellular carcinoma (HCC) diagnosis often relies on imaging characteristics.
- Intraarterial Lipiodol injection is a technique explored for differentiating HCC from benign liver lesions.
- Prolonged contrast medium retention is considered a hallmark of malignant tumors like HCC.
Observation:
- Two cases of liver cavernous hemangioma were studied.
- Lipiodol was injected intraarterially in these hemangioma cases.
- Significant Lipiodol uptake and retention were observed in the hemangiomas for up to 3 months.
Findings:
- Cavernous hemangiomas demonstrated prolonged Lipiodol retention, similar to characteristics expected in HCC.
- The presence of Lipiodol retention in hemangiomas was observed for an extended period (up to 3 months).
- This finding challenges the established diagnostic criteria for differentiating HCC.
Implications:
- Intraarterial Lipiodol injection may not be a reliable standalone method for differentiating HCC from cavernous hemangioma.
- Re-evaluation of diagnostic protocols for liver lesions using Lipiodol is warranted.
- Further research is needed to identify more specific imaging biomarkers for distinguishing malignant and benign liver tumors.